Abstract: Disclosed herein are a polypeptide having cephalosporin C(CPC) acylase activity and a use thereof. More specifically, a mutant CPC acylase comprising a point mutation introduced thereinto, thereby exhibiting improved enzymatic activity and/or stability, and a use of the mutant CPC acylase for producing 7-aminocephalosporanic acid (7-ACA), are provided.

Abstract: This disclosure relates to a composition for the prevention or the treatment of inflammatory skin diseases or severe pruritus comprising an aqueous solubilized ursodeoxycholic acid (UDCA). According to this disclosure, inflammatory skin diseases and severe pruritus such as atopic dermatosis, acne, psoriasis, hives, inflammatory skin disease, seborrheic dermatitis and contact dermatitis can be effectively alleviated or treated. Therefore, the composition comprising aqueous solubilized ursodeoxycholic acid of this disclosure can be best used as a pharmaceutical, food or cosmetic composition, and can be used particularly as an external preparation to exhibit its effect.

Abstract: The present invention relates to a mutated immunoglobulin-binding protein having increased alkaline tolerance and, more specifically, to an immunoglobulin-binding protein in which, with respect to the A-domain of Staphylococcal protein A, or a functional variant thereof, an amino acid at a specific site is mutated and thereby exhibits an increased chemical stability at an alkaline pH value in comparison to a parental molecule. The present invention can provide an antibody-purifying immunoglobulin-binding protein ligand and matrix which have enhanced alkaline tolerance and accordingly enhanced stability in multiple times of alkaline cleaning.

Abstract: A method of producing lycopene, with high productivity by means of a recombinant bacterial strain includes preparing the recombinant vector containing genes encoding proteins, which are required for lycopene biosynthesis. The genes involved in lycopene biosynthesis are crtE with the nucleotide SEQ ID NO: 8, crtB with the nucleotide SEQ ID NO: 3 and crtI with the nucleotide SEQ ID NO: 5 of the Sequence List. The said recombinant vector is transformed into Escherichia coli (hereafter E. coli). The E. coli transformant is cultured to recover lycopene from the culture medium.

Abstract: A method of producing lycopene, with high productivity by means of a recombinant bacterial strain includes preparing the recombinant vector containing genes encoding proteins, which are required for lycopene biosynthesis. The genes involved in lycopene biosynthesis are crtE, crtB and crtI, and at least one of the said three genes (crtE, crtB and crtI) is selected from the group consisting of crtE with the SEQ ID NO:1, crtB with the SEQ ID NO:3 and crtI with the SEQ ID NO:5, of the Sequence List. The said recombinant vector is transformed into Escherichia coli (hereafter E. coli). The E. coli transformant is cultured to recover lycopene from the culture medium.

Abstract: A method of producing lycopene with high productivity by means of a recombinant bacterial strain includes preparing the recombinant vector containing genes encoding proteins, which are required for lycopene biosynthesis. The genes involved in lycopene biosynthesis are crtE, crtB and crtI, and at least one of the said three genes (crtE, crtB and crtI) is selected from the group consisting of crtE with the nucleotide Sequence 1, crtB with the nucleotide Sequence 3 and crtI with the nucleotide Sequence 5, of the Sequence List. The said recombinant vector is transformed into Escherichia coli.

Abstract: There are provided genes involved in the biosynthesis of lycopene and having DNA sequences set forth in SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5 encoding proteins required for the biosynthesis of lycopene, a recombinant vector comprising at least one of the genes, and a mi croorganism transformed with the recombinant vector and having a high content of lycopene. The lycopene is obtained at a yield of 15.3 mg/L and a content of 4.2 mg/gDCW when the recombined E. coli with the crt genes is cultivated, and the lycopene is also obtained with the maximum content of 5.4 mg/gDCW when a microorganism is transformed with the combination of the gene of the present invention and the known genes. Therefore, provided is the lycopene-producing strain having a more increased content of lycopene per dry cell weight than the known lycopene-producing strain with the genes. Accordingly, the genes may be useful to mass-produce lycopene in microorganisms, and also to mass-produce carotenoids.

Abstract: A method of producing lycopene, with high productivity by means of a recombinant bacterial strain includes preparing the recombinant vector containing genes encoding proteins, which are required for lycopene biosynthesis. The genes involved in lycopene biosynthesis are crtE, crtB and crtI, and at least one of the said three genes (crtE, crtB and crtI) is selected from the group consisting of crtE with the nucleotide Sequence 1, crtB with the nucleotide Sequence 3 and crtI with the nucleotide Sequence 5, of the Sequence List. The said recombinant vector is transformed into Escherichia coli (hereafter E. coli). The E. coli transformant is cultured to recover lycopene from the culture medium.

Abstract: The present invention relates to a composition for the prevention or treatment lipid metabolic disorders comprising fucoxanthin or marine plant extract comtaining the same as an effective indredients. Fucoxanthin or a marine plant extract comprising the same is effective in reducing weight increase and reducing triglyceride and cholesterol level in liver tissue, or plasma through inhibiting the synthesis of fatty acid and promoting the oxidation of fatty acid. Therefore, the composition comprising fucoxanthin or a marine plant extract comprising the same as an effective ingredient may be effectively used for the prevention and treatment of lipid metabolic disorders.

Abstract: Disclosed in this invention is a use of pinitol or chiroinositol for protecting the liver.

Abstract: The present invention relates to a method for producing a recombinant polynucleotides comprising the steps of generating a pool of unidirectional single-stranded polynucleotide fragments from two or more homologous double-stranded polynucleotides, conducting a polymerization process comprising multi-cyclic extension reactions using the unidirectional single-stranded polynucleotide fragments as templates and specific oligonucleotides as primers to obtain recombinant polynucleotides, and conducting a polymerase chain reaction using at least one primer to amplify the recombinant polynucleotides; and a method for constructing a recombinant DNA library comprising the steps of inserting the recombinant polynucleotide prepared by the above method into a vector and transforming an expression cell with said vector containing the recombinant polynucleotide to obtain a plurality of mutant clones.